US Food and Drug Administration (FDA) has granted clearance for ZELTIQ Aesthetics to carry out a CoolSculpting procedure at lower temperatures, which will help reduce treatment times.

The non-surgical, clinically proven CoolSculpting procedure selectively reduces fat bulges in problem areas using a patented cooling technology.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

ZELTIQ Aesthetics president Mark Foley said: "This FDA clearance will enable healthcare professionals to perform the CoolSmooth procedure in nearly half the time with the same outcomes, which will significantly enhance the procedural efficiency and profitability for the practise, while also improving the patient experience.

"Through an ongoing investment in R&D and technological innovation, we are pleased to continue to provide our CoolSculpting partners with differentiated solutions that enhance their treatment options."

"The non-surgical, clinically proven CoolSculpting procedure selectively reduces fat bulges in problem areas using a patented cooling technology."

Approval was based on clinical data, which showed optimised temperatures allow shorter treatment times with equivalent benefits, safety, efficacy and customer satisfaction, compared against current CoolSculpting procedures.

In line with this clearance, the company is set to introduce its brand new applicator, CoolSmooth PRO in the second quarter of 2015.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

CoolSmooth PRO is a surface applicator that features non-vacuum based cooling to treat non-pinchable fat bulges such as the outer thigh area.

Approved for non-invasive fat reduction in the abdomen, flank and thighs, the CoolSculpting procedure gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells, without harming surrounding tissue.

New treatment parameters will be provided with the CoolSmooth PRO applicator, which allows control over treatments at colder temperatures.

CoolSmooth PRO applicator features an enhanced strapping system, which offers increased conformity at the treatment site, and improves ease of use and patient comfort.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact